Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumar Prabhash

Showing results (461-470 of 469) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 469 results.
The Lancet Regional Health. Southeast Asia|August 19, 2024
Uniqueness of lung cancer in Southeast AsiaVanita Noronha, Atul Budukh, Pankaj Chaturvedi, et al.
Cancer Cell|November 20, 2018
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain MutationsKanika Bajaj Pahuja, Thong T Nguyen, Bijay S Jaiswal, et al.
JNCI Cancer Spectrum|July 27, 2024
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancersAnant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, et al.
Cancer Letters|April 10, 2025
Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomesRushabh Kothari, Vijay Patil, Ravi Krishna Madala, et al.
Cancer|June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancerVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancerVanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Clinical Lung Cancer|March 6, 2025
Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 PatientsMinit Shah, Vanita Noronha, Vijay Patil, et al.
The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.
Pageof 47

Showing results (461-470 of 469) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 469 results.
The Lancet Regional Health. Southeast Asia|August 19, 2024
Uniqueness of lung cancer in Southeast AsiaVanita Noronha, Atul Budukh, Pankaj Chaturvedi, et al.
Cancer Cell|November 20, 2018
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain MutationsKanika Bajaj Pahuja, Thong T Nguyen, Bijay S Jaiswal, et al.
JNCI Cancer Spectrum|July 27, 2024
Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancersAnant Ramaswamy, Prabhat Bhargava, Biswajit Dubashi, et al.
Cancer Letters|April 10, 2025
Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomesRushabh Kothari, Vijay Patil, Ravi Krishna Madala, et al.
Cancer|June 1, 2019
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancerVijay Maruti Patil, Vanita Noronha, Amit Joshi, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancerVanita Noronha, Vijay Patil, Pankaj Chaturvedi, et al.
Clinical Lung Cancer|March 6, 2025
Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 PatientsMinit Shah, Vanita Noronha, Vijay Patil, et al.
The New England Journal of Medicine|September 9, 2025
Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLCJames Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, et al.
The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.
Pageof 47